FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 巨子生物控股有限公司 呈交日期： 2025年12月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02367 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | ...

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [2][29]. Core Insights - The release of the 2025 version of the basic medical insurance directory continues to support innovation, with 114 new drugs added, including 50 first-class innovative drugs, while 29 drugs were removed due to lack of supply or better alternatives [3]. - The MSCI China Healthcare Index has seen a cumulative increase of 60.9% since the beginning of 2025, outperforming the MSCI China Index by 29.2% [1]. - Despite a recent 9% pullback in the healthcare sector, undervalued stocks present attractive investment opportunities [1][3]. - The trend of innovative drugs going overseas is expected to continue, with a focus on the progress of these products in international markets [1]. - The demand for innovative drug research and development in China is showing signs of recovery, supported by a resurgence in capital market financing and an increase in the scale of overseas transactions [1]. Summary by Sections Industry Research - The report highlights that the adjustment of the medical insurance directory emphasizes support for "true innovation" and "differentiated innovation" [3]. - The first version of the commercial insurance directory includes 19 innovative drugs, which may pave the way for the expansion of commercial medical insurance in China [3]. - The report recommends a more cautious investment approach, focusing on undervalued stocks in the sector [3]. Company Ratings - Recommended companies include: - 三生制药 (Sangfor) with a target price of 37.58 and a potential upside of 29% [2]. - 固生堂 (Gushengtang) with a target price of 44.95 and a potential upside of 58% [2]. - 药明合联 (WuXi AppTec) with a target price of 74.00 and a potential upside of 10% [2]. - 巨子生物 (Giant Biotech) with a target price of 53.89 and a potential upside of 48% [2]. - 信达生物 (Innovent Biologics) with a target price of 110.62 and a potential upside of 29% [2]. - 中国生物制药 (China National Pharmaceutical Group) with a target price of 9.40 and a potential upside of 39% [2].

Macro Economic Overview - China's exports showed a short-term rebound in November, exceeding market expectations, driven by improvements in exports to the EU, Latin America, Japan, South Korea, and Africa, while exports to the US and ASEAN remained weak [2] - The semiconductor exports benefited from the global AI boom, maintaining a high growth rate, reflecting China's ongoing technological advancements [2] - Imports slightly improved due to processing trade, but general trade continued to decline due to weak domestic demand [2] Global Market Performance - The Hang Seng Index closed at 25,765, down 1.23% for the day but up 28.44% year-to-date [3] - The Shanghai Composite Index rose 0.54% to 3,924, with a year-to-date increase of 17.08% [3] - The US markets saw a decline, with the Dow Jones down 0.45% and the S&P 500 down 0.35% [3] Automotive Industry Insights - The Chinese automotive industry is expected to see retail and wholesale sales reach historical highs in 2025, with a more complex landscape anticipated in 2026 due to the phasing out of subsidies [6][7] - Despite challenges from subsidy reductions, retail sales are expected to remain stable, with wholesale volumes projected to grow by 2.9% in 2026 [7] - The competition in the automotive sector is expected to intensify, with new model releases at historical highs and potential price increases in battery costs impacting profit margins [7] Insurance Sector Analysis - The recent adjustment in risk factors for insurance companies aims to encourage long-term equity holdings, potentially releasing a minimum capital of 30.8 billion yuan [9][10] - The adjustment is expected to enhance the capital efficiency of insurance investments in A-shares compared to H-shares, benefiting major players like China Ping An and China Life [11] - The insurance sector maintains a "buy" rating, with recommended stocks including China Ping An, China Life, and AIA Group [12] Pharmaceutical Industry Developments - The MSCI China Healthcare Index has risen by 60.9% year-to-date, outperforming the MSCI China Index [13] - The recent release of the basic medical insurance directory supports innovation, with 114 new drugs added, including 50 innovative drugs [13][14] - The commercial insurance directory's introduction is seen as a significant step towards expanding China's commercial health insurance landscape [14][15]

Core Insights - The article discusses a significant transaction in the A-share market where the controlling shareholder of the company Sanrenxing transferred 8% of its shares for 450 million yuan to Yan Jianya, a newly prominent billionaire in Shaanxi [2][6] - This investment marks Yan Jianya's strategic entry into the marketing services sector, as Sanrenxing is a leading integrated marketing service provider in China [2][5] - The transaction is seen as a strategic move for both parties, with Sanrenxing aiming to optimize its governance and leverage Yan's extensive industry resources [6][10] Company Overview - Sanrenxing, established in 2003, specializes in digital marketing, event services, and campus media, serving major clients like China Mobile and JD.com [2][5] - The company's revenue has declined from 5.65 billion yuan in 2022 to an estimated 4.21 billion yuan in 2024, with net profit dropping from 740 million yuan to 120 million yuan during the same period [2][6] Investment Details - Yan Jianya's acquisition of shares reduces the controlling shareholder's stake from 53.88% to 45.88%, while Yan becomes the second-largest shareholder with over 5% ownership [6][10] - The transaction is framed as a move to introduce a significant strategic investor to enhance Sanrenxing's governance and market credibility [6][10] Strategic Collaboration - Yan Jianya and Sanrenxing have a history of collaboration, with previous investments and partnerships that have built mutual trust and resource sharing [3][7] - The partnership is expected to create synergies between Sanrenxing's marketing capabilities and Yan's ventures in biotechnology and aerospace, potentially expanding Sanrenxing's client base [7][10] Market Impact - The investment is anticipated to enhance Sanrenxing's operational capabilities and market positioning, particularly in high-end manufacturing and military sectors [6][10] - Yan Jianya's growing influence in the A-share market is highlighted by his control over three listed companies, forming a diversified capital matrix that includes biotechnology, aerospace, and marketing [5][10]

Core Viewpoint - The release of the 2025 version of the basic medical insurance directory and the first commercial insurance directory is expected to support innovation in the CXO industry, leading to a potential performance recovery in the second half of the year [1] Summary by Categories Industry Outlook - The report indicates that several companies' core innovative products have been included in the medical insurance directory [1] - Despite ongoing pressures on medical insurance revenue due to macroeconomic conditions and aging populations, attention is drawn to the renewal of national centralized procurement [1] Commercial Insurance - The initial commercial insurance directory is expected to have limited short-term impact on product sales due to the small scale of commercial insurance [1] - However, the significance of the commercial insurance directory is highlighted as it may pave the way for the expansion of commercial medical insurance in China, marking the beginning of a diversified payment system development [1] Company Recommendations - The report recommends buying shares in the following companies: - Sanofi (01530) - Genscript Biotech (02273) - WuXi AppTec (02268) - Genor Biopharma (02367) - Innovent Biologics (01801) - China Biologic Products (01177) [1]

Industry Overview - Collagen masks are mainstream skincare products focused on anti-aging and repair, utilizing collagen as the core ingredient along with auxiliary components to achieve hydration and skin barrier repair [1][2] - The Chinese mask industry is expected to reach a market size of 72.986 billion yuan in 2024, entering a period of adjustment and transformation, facing growth slowdown and intensified competition [1][6] - The collagen market is experiencing explosive growth, with a compound annual growth rate (CAGR) of 41.9% from 2020 to 2023, and retail scale expected to exceed 269.5 billion yuan by 2030 [1][7] Market Dynamics - The market structure in China shows that sheet masks remain dominant, while cream masks are rapidly growing, focusing on hydration and repair needs [1][7] - The competitive landscape features local leaders dominating, niche players breaking through, and international brands penetrating the market, with a clear price gradient and significant differentiation between high, medium, and low-end markets [1][8] Industry Chain - The upstream of the collagen mask industry primarily uses animal-derived collagen, while recombinant collagen is rapidly developing due to its high purity and compatibility with mask formulations [6][10] - The manufacturing process involves various technologies to convert raw materials into different forms and functions of mask products, with sales channels dominated by online e-commerce and deepening offline professional channels [6][10] Current Development - The Chinese mask industry is transitioning into a phase of deep integration after rapid growth, with three emerging drivers leading market changes: consumption upgrades, male skincare market expansion, and personalized demand fostering innovative scenarios [6][7] - The market size is projected to steadily grow to 76.79 billion yuan by 2025 and potentially exceed 146.42 billion yuan by 2030, indicating robust long-term growth prospects [6][7] Key Players - Major companies in the collagen mask industry include Juzi Biotechnology, Huaxi Biotechnology, and Marubi Biotechnology, leveraging differentiated technologies and channel advantages to lead the market [2][10] - The industry is characterized by a multi-faceted competitive ecosystem, with local leaders, niche players, and international brands all contributing to the market dynamics [10] Future Trends - The industry is expected to advance towards high-end technology, refined products, and standardized ecosystems, with a focus on cross-disciplinary technology integration and precise formulations [10][12] - Regulatory tightening is anticipated to accelerate the elimination of smaller brands, increasing market concentration, while leading companies will strengthen their market positions through R&D innovation and global expansion [10][14]

Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a focus on leading brands and potential opportunities in compliance-driven market shifts [1]. Core Insights - The new safety standards for mobile power banks are expected to drive industry transformation, increasing compliance costs and accelerating technological upgrades. This may lead to a shift from a fully competitive market to an oligopoly, benefiting leading brands with strong R&D capabilities [1]. - The "Cultural and Tourism Integration" policy is anticipated to positively impact the service consumption sector, enhancing travel services and creating new products and scenarios in the tourism industry [1]. Market Weekly Review - During the week of December 1-5, the consumer sector saw mixed performance, with home appliances rising by 1.84% while other sectors like food and beverage and beauty care declined by 1.90% and 2.00% respectively. Notable gainers included Anji Food (+50.23%) and Xiaosong Co. (+22.94%), while Rock Co. (-14.84%) and Yitian Intelligent (-7.88%) were among the biggest losers [3][13][14]. Industry News and Key Company Announcements - The Ministry of Culture and Tourism and the Civil Aviation Administration of China released an action plan for the integration of culture, tourism, and civil aviation, aiming for a higher quality of service and broader coverage of travel routes by 2027 [1][16]. - Gree Electric's silicon carbide chip factory is focusing on a strategy of "independent control and open foundry," with over 20 chip design companies as clients, indicating a significant expansion into various sectors including new energy and industrial control [1][16]. - New regulations in the food safety sector have been implemented, enhancing the supervision of liquid food transport and establishing stricter responsibilities for chain restaurants [1][17].

Core Viewpoint - The recent capital layout by Yan Jianya, founder of Juzhi Biotechnology, involves acquiring shares in Sanrenxing Media Group, indicating a strategic investment in a company facing declining performance in recent years [1][2][17]. Company Overview - Sanrenxing Media Group is a comprehensive advertising and marketing service company, focusing on digital marketing, event services, and campus media marketing, with clients from various sectors including telecommunications, finance, consumer goods, and automotive [1][15]. - As of December 5, the total market capitalization of Juzhi Biotechnology is approximately HKD 410.2 billion (around RMB 372.54 billion), while Sanrenxing's market capitalization stands at RMB 64.09 billion [16]. Financial Performance - In 2022, Sanrenxing achieved record revenues of RMB 56.53 billion and a net profit of RMB 7.37 billion [3][18]. - However, the company has experienced a decline in performance over the past two years, with projected revenues for 2024 dropping to RMB 42.08 billion (a 20% decrease) and net profit falling to RMB 1.23 billion (a 76.65% decline) [4][18]. - For the first three quarters of the current year, Sanrenxing reported revenues of RMB 25.69 billion, down 16.72% year-on-year, and a net profit of RMB 1.45 billion, down 20.48% [4][18]. Investment Details - Yan Jianya's acquisition involves the transfer of 16.865 million unrestricted shares from multiple controlling shareholders of Sanrenxing, totaling approximately RMB 4.51 billion [1][19]. - Post-transaction, Yan will hold an 8% stake in Sanrenxing, becoming the second-largest shareholder after the controlling shareholders [1][15]. Strategic Implications - The investment is seen as a strategic move for Yan, allowing him to leverage Sanrenxing's extensive marketing resources, including a nationwide campus media network covering over 900 universities [20]. - Sanrenxing has established partnerships with major internet media platforms, enhancing its digital marketing capabilities and transitioning towards a technology-driven marketing model [21]. Industry Context - The beauty industry, including companies like Juzhi Biotechnology, faces challenges in balancing brand building and effective advertising, with marketing costs rising significantly [22][23]. - Juzhi's sales expense ratio has increased from 22.30% in 2021 to 36.25% in 2024, reflecting the industry's trend towards higher marketing investments [23]. Future Outlook - The collaboration with Sanrenxing is expected to provide Juzhi Biotechnology with enhanced marketing strategies and execution support, aiding in the establishment of a more sustainable brand communication system [25]. - The beauty sector is witnessing a shift towards ecological layouts, with companies expanding their investment portfolios and seeking synergies among brands to create value [26][27].

Market Performance - The market opened high on December 8, with the Shanghai Composite Index rising by 0.54%, the Shenzhen Component Index increasing by 1.39%, and the ChiNext Index up by 2.6% [1][2] - The total trading volume in the Shanghai and Shenzhen markets reached 2.05 trillion, an increase of 312.7 billion compared to the previous trading day, with over 3,400 stocks rising [1] Sector Highlights - The Fujian sector saw a significant surge, with Anji Food achieving five consecutive trading limits, and over ten stocks including Shuhua Sports and Fujian Jinsen hitting the daily limit [3] - The AI industry chain is experiencing continuous catalysis, with companies like Tianfu Communication and Guangpu Technology seeing stock prices rise over 10% [6] - The commercial aerospace concept remains strong, with Shunhao Co. achieving six trading limits in seven days, and Longzhou Co. hitting four consecutive limits [7] Pharmaceutical Sector - The pharmaceutical sector showed strong fluctuations, with multiple stocks rising over 10% following the announcement of the updated national medical insurance directory, which now includes 3,253 types of drugs [9][10] - Sixteen A-share listed pharmaceutical companies reported that their products were included in the national medical insurance directory or the innovative drug directory [10] Consumer Sector - In the Hong Kong market, consumer stocks experienced a downturn, with Pop Mart dropping nearly 9% and several related stocks declining over 3% [11] - Deutsche Bank noted that Pop Mart is increasing production capacity significantly, which may indicate a potential decline in brand heat due to mass production [12]

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% over the next six months [29]. Core Insights - The report highlights the importance of focusing on segments with marginal improvements and stable growth within the consumer sector, particularly in the home appliance and beauty industries [3][4]. - The tourism sector is showing potential for recovery, with leading companies like Ctrip and Huazhu Hotels responding quickly to changing consumer demands [3]. - The beauty industry is experiencing steady growth, with a recommendation to monitor leading brands that adapt swiftly to market dynamics [3]. - The liquor industry is facing challenges, with a notable decline in net profits for many companies in Q3 2025 compared to Q2 2025, but leading firms are expected to gain market share [4][20]. - The snack segment is showing a divergence in performance, with certain products like konjac continuing to thrive, while dairy companies are entering a recovery phase [4][25]. Summary by Sections Home Appliances - The home appliance sector is experiencing a downturn, with air conditioning production down 27.9% year-on-year in October 2025, and sales down 20.1% [27]. - Central air conditioning sales reached 11.2 billion yuan in October 2025, facing downward pressure [27]. - Refrigerator production decreased by 9.8% year-on-year, while washing machine production saw a slight decline of 0.2% [27]. Social Services - The report emphasizes the need to focus on leading companies that can adapt to changing consumer demands in the social services sector, particularly in tourism and beauty [3][4]. Food and Beverage - Alcohol - The report notes a significant decline in net profits for many liquor companies in Q3 2025, with a focus on high-end and mid-range liquor brands expected to perform better [4][20]. - The average price of pork in the wholesale market increased by 0.2% to 17.68 yuan per kilogram as of December 5, 2025 [25]. Food and Beverage - General - The snack segment is experiencing a mixed performance, with konjac products showing strong growth potential [4][25]. - Dairy companies are expected to enter a recovery phase as supply and demand dynamics improve [4][25]. Cultural Communication - The report suggests that media companies should focus on segments related to spiritual needs and consumer sentiment to capture opportunities [4][17].